Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.
Noxopharm Limited has raised nearly $2.5 million by selling its entire shareholding in Nyrada Inc, a strategic move that provides non-dilutive funds to support its operations. This capital will enable the company to advance its HERACLES clinical trial and invest in its R&D pipeline, reinforcing its commitment to innovative technology and drug development.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company is known for its pioneering technology aimed at improving the safety profile of mRNA medicines. Noxopharm leverages in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on its Sofra™ and Chroma™ technology platforms, which target inflammation, autoimmunity, mRNA drug enhancement, and oncology.
Average Trading Volume: 93,059
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.46M
See more data about NOX stock on TipRanks’ Stock Analysis page.